SEOUL (Reuters) - Shares in Samsung BioLogics Co Ltd fell over 18 percent on Wednesday as South Korea's watchdog Financial Supervisory Service provisionally decided it had breached accounting rules.
Shares in Samsung C&T Corp , which holds a 43 percent stake in drug contract manufacturer Samsung BioLogics, also fell more than 5 percent.
Samsung BioLogics said in a regulatory filing that it will prove it had engaged in proper accounting practices.
(Reporting by Joyce Lee; Editing by Stephen Coates)
Disclaimer: No Business Standard Journalist was involved in creation of this content